Bone marrow transplantation for myelodysplasia

Blood Reviews

Volumn 14, Issue 2, 2000, Pages 63-77

  Anderson, J E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN;

AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; CYTOGENETICS; HLA MATCHING; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REVIEW; SEX DIFFERENCE; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

EID: 0033865415     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0126     Document Type: Review

References (61)

1. Bennett J. M., Catovsky D., Daniel M. T. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189-199.
2. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 6:1992;52-59.
3. Sanz G. F., Sanz M. A., Vallespi T. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a mutivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395-408.
4. Greenberg P., Cox C., LeBeau M. M. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
5. Harris N. L., Jaffe E. S., Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 17:1999;3835-3849.
6. Morel P., Hebbar M., Lai J-L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 7:1993;1315-1323.
7. Cazzola M., Anderson J. E., Ganser A., Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 83:1998;910-935.
8. Silverman L. R., Demakos E. P., Peterson B., Odchimar-Reissig R., Nelson D., Kornblith A. B., Stone R., Holland J. C., Powell B. L., DeCastro C., Ellerton J., Larson R. A., Schiffer C. A., Holland J. F. A randomized controlled trial of subcutaneous azacitidine (AZA-C) in patients with the myelodysplastic syndrome (MDS): A study of the Cancer and Leukemia Group B (CALGB). Proceedings of ASCO Meeting, Abstract #53. 17:1998;14a.
9. Gassmann W., Schmitz N., Loffler H., De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol. 33:1996;196-205.
10. Appelbaum F. R., Storb R., Ramberg R. E. Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med. 100:1984;689-693.
11. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., Niederwieser D., Labopin M., Walter-Noel M. P., Bacigalupo A., Jacobsen N., Ljungman P., Carreras E., Kolb H. J., Aul C., Apperley J. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 21:1998;255-261.
12. Arnold R., de Witte T., van Biezen A., Hermans J., Jacobsen N., Runde V., Gratwohl A., Apperley J. F. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. Bone Marrow Transplant. 21:1998;1213-1216.
13. Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Shulman H., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney K., Martin P. J., Sanders J. E., Sullivan K. M., Thomas E. D., Witherspoon R. P., Hansen J. A., Storb R. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 82:1993;677-681.
14. Sutton L., Chastang C., Ribaud P., Jouet J-P., Kuentz M., Attal M., Reiffers J., Tigaud J-M., Rio B., Dauriac C., Legros M., Dreyfus F., Lioure B., Troussard X., Milpied N., Witz F., Oriol P., Cahn J-Y., Michallet M., Gluckman E., Ifrah N., Pico J-L., Vilmer E., Leblond V. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Societe Francaise de Greffe de Moelle. Blood. 88:1996;358-365.
15. Nevill T. J., Fung H. C., Shepherd J. D., Horsman D. E., Nantel S. H., Klingemann H-G., Forrest D. L., Toze C. L., Sutherland H. J., Hogge D. E., Naiman S. C., Le A., Brockington D. A., Barnett M. J. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 92:1998;1910-1917.
16. Ballen K. K., Gilliland D. G., Guinan E. C., Hsieh C-C., Parsons S. K., Rimm I. J., Ferrara J. L. M., Bierer B. E., Weinstein H. J., Antin J. H. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 20:1997;737-743.
17. Locatelli F., Niemeyer C., Angelucci E., Bender-Gotze C., Burdach S., Ebell W., Friedrich W., Hasle H., Hermann J., Jacobsen N., Klingebiel T., Kremens B., Mann G., Pession A., Peters C., Schmid H-J., Stary J., Suttorp M., Uderzo C., van't Veer-Korthof E. T., Vossen J., Zecca M., Zimmermann M. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 15:1997;566-573.
18. O'Donnell M. R., Long G. D., Parker P. M., Niland J., Nademanee A., Amylon M., Chao N., Negrin R. S., Schmidt G. M., Slovak M. L., Smith E. P., Snyder D. S., Stein A. S., Traweek T., Glume K. G., Forman S. J. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 13:1995;2973-2979.
19. Mattijssen V., Schattenberg A., Schaap N., Preijers F., De Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant. 19:1997;791-794.
20. Anderson J. E., Appelbaum F. R., Schoch G., Gooley T., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Chauncey T., Clift R. A., Deeg H. J., Doney K., Flowers M., Hansen J. A., Martin P. J., Matthews D. C., Nash R. A., Sanders J. E., Shulman H., Sullivan K. M., Witherspoon R. P., Storb R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 14:1996;220-226.
21. Anderson J. E., Appelbaum F. R., Schoch G., Gooley T., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Chauncey T. R., Clift R. A., Doney K., Flowers M., Hansen J. A., Martin P. J., Matthews D. C., Sanders J. E., Shulman H., Sullivan K. M., Witherspoon R. P., Storb R. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood. 87:1996;51-58.
22. Ratanatharathorn V., Karanes C., Uberti J., Lum L. G., de Planque M. M., Schultz K. R., Cronin S., Dan M. E., Mohamed A., Hussein M., Sensenbrenner L. L. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 81:1993;2194-2199.
23. Demuynck H., Verhoef G. E. G., Zachee P., Emonds M. P., van der Schuren E., van den Berghe H., Vandenberghe P., Casteels-Van Daele M., Boogaerts M. A. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant. 17:1996;745-751.
24. Appelbaum F. R., Barrall J., Storb R., Ramberg R., Doney K., Sale G. E., Thomas E. D. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol. 15:1987;1134-1139.
25. Appelbaum F. R., Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia. 12:1998;S25-S29.
26. Deeg, H. J. Shulman, H. M. Anderson, J. E. Bryant, E. M. Gooley, T. A. Slattery, J. T. Anasetti, C. Fefer, A. Storb, R. Appelbaum, F. R. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55-66 years of age. Blood.
27. Pedersen-Bjergaard J., Pedersen M., Roulston D., Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 86:1995;3542-3552.
28. Stone R. M. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood. 83:1994;3437-3440.
29. Witherspoon R. P., Deeg H. J. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica. 84:1999;1085-1087.
30. Le Maignan C., Ribaud P., Maraninchi D. Bone marrow transplantation for mutagen-related leukemia or myelodysplasia. Exper Hematol. 18:1990;660.
31. Bandini G., Rosti G., Calori E., Albertazzi L., Tura S. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol. 75:1990;442-443.
32. De Witte T. Response to Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol. 75:1990;443-444.
33. Bunin N. J., Casper J. T., Chitambar C. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 6:1988;1851-1855.
34. Castro-Malaspina H., Collins J. E. R., Gajewski J., Harris R., Ramsay N., Deeg H. J. Unrelated donor marrow transplantation for myelodysplastic syndromes (MDS). Blood. 90:1997;106a.
35. Anderson J. E., Anasetti C., Appelbaum F. R., Schoch G., Gooley T. A., Hansen J. A., Buckner C. D., Sanders J. E., Sullivan K. M., Storb R. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 93:1996;59-67.
36. Sierra J., Carreras E., Rozman C., Champlin R., Rowlings P., Horowitz M. Bone Marrow transplantation for myelodysplasia: the IBMTR data. (Abstract). Leuk Res. 21:1997;S51.
37. Kernan N. A., Bartsch G., Ash R. C. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 328:1993;593-602.
38. Dresse M-F., Boogaerts M., Vermylen C., Noens L., Ferrant A., Schots R., Doyen C., Bron D., Berneman Z., Ferster A., Benoit Y., Demuynck H., Beguin Y. The Belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor. Haematologica. 84:1999;637-642.
39. Bjerke J., Anasetti C., Gooley T., Appelbaum F., Hansen J., Anderson J., Slattery J., Storb R., Deeg H. J. Unrelated Donor (URD) Bone Marrow Transplantation (BMT) for Refractory Anemia (RA). Blood. 92:1998;142a.
40. 2in myelodysplastic syndrome. Blood. 94:1999;661a.
41. Anderson J. E., Gooley T. A., Schoch G. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 89:1997;2578-2585.
42. Alessandrino E. P., Astori C., Van Lint M. T. Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: outcome of 90 adult patients. Leuk Res. 21:1997;S52.
43. DeWitte T., Zwaan F., Hermans J. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol. 74:1990;151-155.
44. Clift R. A., Buckner C. D., Appelbaum F. R., Schoch G., Petrsen F. B., Bensinger W. I., Sanders J., Sullivan K. M., Storb R., Singer J., Hansen J. A., Thomas D. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clinic Oncol. 10:1992;1723-1729.
45. Karanes C., Abella E., Du W., Klein J., Dansey R., Cassells L., Peters W., Baynes R. Allogeneic bone marrow transplantation (alloBMT) in myelodysplastic syndromes (MDS). Blood. 92:1998;659a.
46. Anderson J. E., Appelbaum F. R., Deeg H. J., Storb R. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogeneic marrow transplantation (BMT) for advanced myelodysplastic syndrome. Leuk Res. 23:1999;S83.
47. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 90:1997;417a.
48. Castro-Malaspina H., Childs B., Papadopoulos E. T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes. Leuk Res. 21:1997;S51.
49. O'Donnell P. V., Noga S. J., Grever M., Vogelsang G. B., Jones R. J. Using engineered allografts to improve transplant outcome in myelodysplastic syndrome (MDS). Blood. 90:1997;229a.
50. Busque L., Kohler S., DeHart D. High incidence of polyclonal granulocytopoiesis in myelodysplastic syndromes (MDS). Blood. 82:1993;196a.
51. Culligan D. J., Bowen D. T., May A., White D., Padua R. A., Burnett A. K. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. Br J Haematol. 89:1995;675-677.
52. Ito T., Ohashi H., Kagami Y., Ichikawa A., Saito H., Hotta T. Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. Leukemia. 8:1994;839-843.
53. Delforge M., Demuynck H., Vandenberghe P. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 86:1995;3660-3667.
54. Carella A. M., Dejana A., Lerma E. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 95:1996;127-130.
55. De Witte T., Van Biezen A. V., Hermans J. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood. 90:1997;3853-3857.
56. Demuynck H., Delforge M., Verhoef G. E. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol. 92:1996;351-359.
57. Wattel E., Solary E., Caillot D. Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS). Leuk Res. 21:1997;S52
58. Oberg G., Simonsson B., Smedmyr B. Is haematological reconstitution seen after ABMT in MDS patients? Bone Marrow Transplant. 4:1989;52.
59. Laporte J. P., Isnard F., Lesage S. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): A pilot study. Leukemia. 7:1993;2030-2203.
60. Schiller G., Lill M., Lee M., Sawyer C., Paquette R., Territo M. Transplantationn of autologous peripheral blood progenitor cells for patients with secondary acute myelogenous leukemia. Blood. 90:1997;85a.
61. De Witte T., Suciu S., Verhoef G., Labar B., Archimbaud E., Aul C., Selleslag D., Ferrant A., Wijermans P., Mandelli F., Smadori S., Jehn U., Muus P., DeMuynck H., Dardenne M., Zittoun R., Willemze R., Gratwohl A., Apperley J. Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk MDS and secondary AML (SAML). Blood. 92:1998;714a.